Authors

Chung-Han (Joe) Lee, MD, PhD

Latest:

Dr. Lee on Second-Line Treatment Options in RCC

Chung-Han Lee, MD, PhD, discusses second-line treatment options in renal cell carcinoma.

Chung-Han Lee, MD, PhD

Latest:

Dr Lee on Extended Follow-Up With Pembrolizumab and Lenvatinib in Pretreated mRCC

Chung-Han Lee, MD, PhD, discusses the final results of the phase 2 cohort of a phase 1/2 trial evaluating lenvatinib plus pembrolizumab in patients with pretreated metastatic clear cell renal cell carcinoma.

Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center

Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Center

Chunkit Fung, MD, MS

Latest:

Androgen Deprivation Therapy and Cardiovascular Risk in Prostate Cancer

Accumulating evidence suggests that androgen deprivation therapy for prostate cancer increases the risk of cardiovascular morbidity and mortality, though not all studies demonstrate an association

Ciara O'Sullivan, MB, BCh

Latest:

Dr. O'Sullivan on Individualized HER2-Targeted Therapy in HER2+ Breast Cancer

Ciara O'Sullivan, MB, BCh, senior associate consultant, assistant professor of oncology, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses how HER2-targeted treatment can be more individualized in the treatment of patients with HER2-positive breast cancer.

C.J. Stimson, MD, JD

Latest:

Wholesale Medicine: The Why and How of Physician Engagement in Healthcare Policy

This article discusses the wholesale side of medicine, exploring the why and how of physician involvement in healthcare policy.

Claire Crowley, RN, Memorial Sloan Kettering Cancer Center

Claire H. Johnston

Latest:

Clinical Oncology in the 21st Century: Reflections on how Healthcare Providers Should Manage Their Public Personas on Social Media

It is important that clinicians engage with social media, since reputations are at risk by not knowing what is being said, shared, and discussed online about them online.

Claire Harrison, MD

Latest:

Ruxolitinib Versus Best Available Therapy for Polycythaemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomised Trial

Claire Harrison, MD, reviews the use of ruxolitinib in patients who are ineligible for hydroxycarbamide for the management of polycythemia vera (PV).

Claire Manuszak, BS

Latest:

Phase I Study With Prexasertib and LY3300054 in Ovarian Cancer

Claire Manuszak, BS, discusses a phase I study (NCT03495323) with prexasertib (LY2606368) and LY3300054 in ovarian cancer.

Claire Verschraegen, MD

Latest:

Dr Verschraegen on Toxicities Associated with Single-agent vs Doublet Immunotherapy in Melanoma

Claire F. Verschraegen, MD, discusses adverse effects that are commonly associated with the use of single-agent nivolumab vs the combination of ipilimumab plus nivolumab in melanoma.

Clancy Clark, MD

Latest:

Advances in the Management of Hepatic and Pancreatic Malignancies

Perry Shen, MD, FACS, and Clancy Clark, MD, from Wake Forest Baptist Health Comprehensive Cancer Center, discuss advances in the management of hepatic and pancreatic malignancies.

Clara Hwang, MD

Latest:

Dr Hwang on Considering AEs Associated With FDA-Approved Agents in Nonmetastatic Prostate Cancer

Clara Hwang, MD, discusses adverse effects associated with FDA-approved agents for patients with nonmetastatic prostate cancer.

Clarke A. Low, MD

Latest:

Dr. Low on Osimertinib Versus Dacomitinib in EGFR-Mutant NSCLC

Clarke A. Low, MD, discusses osimertinib (Tagrisso) versus dacomitinib (Vizimpro) in EGFR-mutant non–small cell lung cancer.

Claud Grigg, MD

Latest:

Dr. Grigg Discusses CABOSUN Trial in mRCC

Claud Grigg, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the design and results of the CABOSUN trial in metastatic renal cell carcinoma.

Claud M. Grigg Jr, MD

Latest:

Dr. Grigg on the Results of the CheckMate-214 Trial in RCC

Claud M. Grigg, Jr., MD, discusses the results of the CheckMate-214 trial in renal cell carcinoma.

Claude Denham, MD

Latest:

Dr. Denham on Hyperprogression in Patients With NSCLC

Claude Denham, MD, Baylor Medical Center, discusses the manifestation of hyperprogression in patients with non–small cell lung cancer (NSCLC) who have been treated with immunotherapy.

Claudia Henschke, MD, PhD

Latest:

Lung Cancer Screening Needs to Remain State-of-the-Art

In CT screening for lung cancer, the regimen of screening is a critical factor in diagnosing lung cancer early while limiting unnecessary tests and invasive procedures.

Claudine Isaacs, MD

Claudine Isaacs, MD is Professor of Medicine and Oncology and Associate Director for Clinical Research at the Lombardi Comprehensive Cancer Center.

Latest:

Dr Isaacs on Establishing Consensus on DESTINY-Breast09 Data in HER2+ Metastatic Breast Cancer

Claudine Isaacs, MD, discusses how to integrate data from the phase 3 DESTINY-Breast09 trial into the HER2-positive metastatic breast cancer paradigm.